Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AKBA, unsubscribe in one click. Privacy
AKBA reported $155.5M in cash and short-term investments (as of Jun 30, 2026) and used about $8.9M/quarter in operations, an estimated runway of 52.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AKBA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 19,219,819 | 6.94% | 2025-12-31 |
| John P. Butler CEO and President, Director · +3.04M options |
Insider | 3,878,492 | 1.40% | 2026-08-06 |
| Steven Keith Burke SVP, Chief Medical Officer · +612,300 options |
Insider | 948,432 | 0.34% | 2026-02-02 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer · +320,000 options |
Insider | 616,616 | 0.22% | 2026-06-29 |
| Carolyn M. Rucci SVP, Chief Legal Officer · +270,000 options |
Insider | 588,378 | 0.21% | 2026-02-02 |
| Nicholas Grund Chief Commercial Officer · +612,300 options |
Insider | 561,750 | 0.20% | 2026-02-02 |
| Richard C Malabre SVP, Chief Accounting Officer · +568,000 options |
Insider | 299,390 | 0.11% | 2026-02-02 |
| Adrian Adams Director · +107,200 options |
Insider | 236,200 | 0.09% | 2026-06-17 |
| Michael W Rogers Director · +107,200 options |
Insider | 197,429 | 0.07% | 2026-06-17 |
| Cynthia Smith Director · +107,200 options |
Insider | 196,633 | 0.07% | 2026-06-17 |
| Myles Wolf Director · +107,200 options |
Insider | 169,081 | 0.06% | 2026-06-17 |
| Ron Frieson Director · +107,200 options |
Insider | 165,200 | 0.06% | 2026-06-17 |
Share count 277,106,245 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AKBA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →